EMA started evaluation of the first batch of data from animal studies and clinical trials. Credit: MasterTux from Pixabay.

The human medicines committee (CHMP) of the European Medicines Agency (EMA) has initiated a rolling review of data on Celltrion’s monoclonal antibody regdanvimab (CT-P59) for Covid-19 treatment.

Regdanvimab works against Covid-19 and is designed to bind to SARS-CoV-2 spike protein. When it attaches to the spike protein, the virus’ ability to enter the cells in the body is reduced.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

This can potentially lower the requirement for hospitalisation in patients with mild to moderate Covid-19.

Rolling review is a regulatory tool used by the agency to expedite the evaluation of a promising medicine or vaccine in the time of a public health emergency.

The latest development is based on preliminary data from an ongoing study analysing regdanvimab’s ability in treating Covid-19.

The agency is yet to evaluate the full dataset, so any conclusions on the benefit-risk balance of the medicine cannot be made.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

EMA noted that it began the evaluation of the first batch of data from animal studies (non-clinical data) and clinical trials, apart from data on the medicine’s quality.

As per the rolling review, EMA will analyse all data on regdanvimab when it becomes available. The process will carry on till sufficient evidence is available for supporting a formal marketing authorisation application.

Furthermore, the medicine’s compliance with the usual standards for effectiveness, safety and quality will be evaluated.

While the overall review timeline cannot be forecast yet, the process should be quicker than a regular evaluation due to the time gained during the rolling review.

Earlier this month, the EMA had started analysing antibody therapies of Eli Lilly and Regeneron for use in Covid-19 patients.

Earlier this month, Novavax announced that multiple regulatory authorities including EMA started the rolling review process for authorisation of its Covid-19 vaccine, NVX-CoV2373.